Literature DB >> 16788932

Endobronchial photodynamic therapy for lung cancer.

Gregory M Loewen1, Ravindra Pandey, David Bellnier, Barbara Henderson, Thomas Dougherty.   

Abstract

BACKGROUND AND
OBJECTIVE: Endobronchial photodynamic therapy (PDT) is a minimally invasive technique for the palliation of major airway obstruction from lung cancer, and for the treatment of endobronchial microinvasive lung cancer. STUDY
DESIGN: Results of reported clinical trials were compared, and the author's preliminary results with second generation photosensitizers were also reviewed.
RESULTS: A review of the clinical experience with endobronchial PDT is provided. Potential advantages of PDT include the duration of palliation achieved through the delayed cellular effects of PDT within tumor. Side-effects from FDA-approved photosensitizer (Photofrin, Porfimer sodium, Axcan Scandipharm, Montreal, Quebec) include skin photosensitivity. HPPH (2-[1-hexyloxyethyl]-2 devinyl pyropheophorbide) is an example of a second-generation photosensitize that shows promise in the treatment of lung cancer, and appears to be free from significant skin photosensitivity.
CONCLUSION: PDT is an effective tool for the palliation of endobronchial lung cancers which obstruct the central airways and is also effective for the treatment of central microinvasive carcinoma and carcinoma in situ of the central airways. Copyright 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16788932     DOI: 10.1002/lsm.20354

Source DB:  PubMed          Journal:  Lasers Surg Med        ISSN: 0196-8092            Impact factor:   4.025


  31 in total

1.  Optimal photosensitizers for photodynamic therapy of infections should kill bacteria but spare neutrophils.

Authors:  Masamitsu Tanaka; Manabu Kinoshita; Yasuo Yoshihara; Nariyoshi Shinomiya; Shuhji Seki; Koichi Nemoto; Takahiro Hirayama; Tianhong Dai; Liyi Huang; Michael R Hamblin; Yuji Morimoto
Journal:  Photochem Photobiol       Date:  2011-10-31       Impact factor: 3.421

2.  A Phase I Study of Light Dose for Photodynamic Therapy Using 2-[1-Hexyloxyethyl]-2 Devinyl Pyropheophorbide-a for the Treatment of Non-Small Cell Carcinoma In Situ or Non-Small Cell Microinvasive Bronchogenic Carcinoma: A Dose Ranging Study.

Authors:  Samjot Singh Dhillon; Todd L Demmy; Sai Yendamuri; Gregory Loewen; Chukwumere Nwogu; Michele Cooper; Barbara W Henderson
Journal:  J Thorac Oncol       Date:  2015-12-22       Impact factor: 15.609

3.  The role of airway stent placement in the management of tracheobronchial stenosis caused by inoperable advanced lung cancer.

Authors:  Kinya Furukawa; Junzo Ishida; Gaku Yamaguchi; Jitsuo Usuda; Hidemitsu Tsutsui; Makoto Saito; Chimori Konaka; Harubumi Kato
Journal:  Surg Today       Date:  2010-03-26       Impact factor: 2.549

4.  Treatment planning using tailored and standard cylindrical light diffusers for photodynamic therapy of the prostate.

Authors:  Augusto Rendon; J Christopher Beck; Lothar Lilge
Journal:  Phys Med Biol       Date:  2008-02-05       Impact factor: 3.609

5.  Effect of 630-NM pulsed laser irradiation on the proliferation of HeLa cells in Photofrin(®)-mediated photodynamic therapy.

Authors:  Yuichi Miyamoto; Daisuke Nishikiori; Fumika Hagino; Masayoshi Wakita; Ichiro Tanabe; Masahiro Toida
Journal:  Laser Ther       Date:  2011

6.  Photodynamic therapy using intra-articular Photofrin for murine MRSA arthritis: biphasic light dose response for neutrophil-mediated antibacterial effect.

Authors:  Masamitsu Tanaka; Manabu Kinoshita; Yasuo Yoshihara; Nariyoshi Shinomiya; Shuhji Seki; Koichi Nemoto; Michael R Hamblin; Yuji Morimoto
Journal:  Lasers Surg Med       Date:  2011-03       Impact factor: 4.025

7.  Indium as a central metal enhances the photosensitizing efficacy of benzoporphyrin derivatives.

Authors:  Courtney Saenz; Manivannan Ethirajan; Gary Iacobucci; Ankit Pandey; Joseph R Missert; Mahabeer P Dobhal; Ravindra K Pandey
Journal:  J Porphyr Phthalocyanines       Date:  2011-11       Impact factor: 1.811

Review 8.  Photodynamic therapy of cancer: an update.

Authors:  Patrizia Agostinis; Kristian Berg; Keith A Cengel; Thomas H Foster; Albert W Girotti; Sandra O Gollnick; Stephen M Hahn; Michael R Hamblin; Asta Juzeniene; David Kessel; Mladen Korbelik; Johan Moan; Pawel Mroz; Dominika Nowis; Jacques Piette; Brian C Wilson; Jakub Golab
Journal:  CA Cancer J Clin       Date:  2011-05-26       Impact factor: 508.702

9.  Hexylether derivative of pyropheophorbide-a (HPPH) on conjugating with 3gadolinium(III) aminobenzyldiethylenetriaminepentaacetic acid shows potential for in vivo tumor imaging (MR, Fluorescence) and photodynamic therapy.

Authors:  Joseph A Spernyak; William H White; Manivannan Ethirajan; Nayan J Patel; Lalit Goswami; Yihui Chen; Steven Turowski; Joseph R Missert; Carrie Batt; Richard Mazurchuk; Ravindra K Pandey
Journal:  Bioconjug Chem       Date:  2010-05-19       Impact factor: 4.774

10.  PDT: What's Past Is Prologue.

Authors:  Keith A Cengel; Charles B Simone; Eli Glatstein
Journal:  Cancer Res       Date:  2016-05-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.